canakinumab
ILARIS can cause serious side effects, including increased risk of serious infections. ILARIS can lower the ability of your immune system to fight infections.,Canakinumab, sold under the brand name Ilaris, is a medication for the treatment of systemic juvenile idiopathic arthritis, active Still's disease, including ... ,Canakinumab is an interleukin-1β (IL-1β) blocker, which works to suppress the production of an inflammatory protein. Increased levels of IL-1β cause ... ,Canakinumab injection is used to treat cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells ... ,Canakinumab is a human monoclonal antibody that selectively targets interleukin-1β. It has no cross-reactivity with other members of the interleukin-1 family, ... ,由 E Dhimolea 著作 · 2010 · 被引用 245 次 — Canakinumab is a human IgGκ monoclonal antibody targeting IL-1β that was developed by Novartis for the treatment of immune disorders. The drug was granted ... ,Canakinumab is an interleukin-1β blocker used to treat Periodic Fever Syndromes such as Cryopyrin-Associated Periodic Syndromes (CAPS) and Familial ... ,Canakinumab may help to lessen the symptoms, such as rash, joint/muscle pain, fever, eye redness, and tiredness.Canakinumab is also used to treat gout attacks ( ... ,Canakinumab should be used as an on-demand therapy to treat gouty arthritis attacks. The recommended dose of canakinumab for adult patients with gouty arthritis ...
| 相關軟體 Canvas X 資訊 | |
|---|---|
 canakinumab 相關參考資料
Autoinflammatory Disease Treatment | ILARIS® ...
ILARIS can cause serious side effects, including increased risk of serious infections. ILARIS can lower the ability of your immune system to fight infections. https://www.ilaris.com Canakinumab
Canakinumab, sold under the brand name Ilaris, is a medication for the treatment of systemic juvenile idiopathic arthritis, active Still's disease, including ... https://en.wikipedia.org Canakinumab (Ilaris)
Canakinumab is an interleukin-1β (IL-1β) blocker, which works to suppress the production of an inflammatory protein. Increased levels of IL-1β cause ... https://rheumatology.org Canakinumab (Subcutaneous Route)
Canakinumab injection is used to treat cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells ... https://www.mayoclinic.org Canakinumab - an overview | ScienceDirect Topics
Canakinumab is a human monoclonal antibody that selectively targets interleukin-1β. It has no cross-reactivity with other members of the interleukin-1 family, ... https://www.sciencedirect.com Canakinumab - PMC
由 E Dhimolea 著作 · 2010 · 被引用 245 次 — Canakinumab is a human IgGκ monoclonal antibody targeting IL-1β that was developed by Novartis for the treatment of immune disorders. The drug was granted ..... https://www.ncbi.nlm.nih.gov Canakinumab: Uses, Interactions, Mechanism of Action
Canakinumab is an interleukin-1β blocker used to treat Periodic Fever Syndromes such as Cryopyrin-Associated Periodic Syndromes (CAPS) and Familial ... https://go.drugbank.com Ilaris (canakinumab) dosing, indications, interactions, ...
Canakinumab may help to lessen the symptoms, such as rash, joint/muscle pain, fever, eye redness, and tiredness.Canakinumab is also used to treat gout attacks ( ... https://reference.medscape.com Ilaris, INN-canakinumab
Canakinumab should be used as an on-demand therapy to treat gouty arthritis attacks. The recommended dose of canakinumab for adult patients with gouty arthritis ... https://www.ema.europa.eu |